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Background: Postmenopausal hormone therapy (HRT) and oral contraceptive (OC) use have in several studies been
reported to be associated with a decreased colorectal cancer (CRC) risk. However, data on the association between
HRT and OC and risk of different clinicopathological and molecular subsets of CRC are lacking. The aim of this
molecular pathological epidemiology study was therefore to evaluate the associations between HRT and OC use
and risk of specific CRC subgroups, overall and by tumour site.
Method: In the population-based prospective cohort study Mamö Diet and Cancer, including 17035 women, 304
cases of CRC were diagnosed up until 31 December 2008. Immunohistochemical expression of beta-catenin, cyclin
D1, p53 and MSI-screening status had previously been assessed in tissue microarrays with tumours from 280 cases.
HRT was assessed as current use of combined HRT (CHRT) or unopposed oestrogen (ERT), and analysed among
12583 peri-and postmenopausal women. OC use was assessed as ever vs never use among all women in the
cohort. A multivariate Cox regression model was applied to determine hazard ratios for risk of CRC, overall and
according to molecular subgroups, in relation to HRT and OC use.
Results: There was no significantly reduced risk of CRC by CHRT or ERT use, however a reduced risk of T-stage 1–2
tumours was seen among CHRT users (HR: 0.24; 95% CI: 0.09-0.77).
Analysis stratified by tumour location revealed a reduced overall risk of rectal, but not colon, cancer among CHRT
and ERT users, including T stage 1–2, lymph node negative, distant metastasis-free, cyclin D1 - and p53 negative
tumours.
In unadjusted analysis, OC use was significantly associated with a reduced overall risk of CRC (HR: 0.56; 95% CI:
0.44-0.71), but this significance was not retained in adjusted analysis (HR: 1.05: 95% CI: 0.80-1.37). A similar risk
reduction was seen for the majority of clinicopathological and molecular subgroups.
Conclusion: Our findings provide information on the relationship between use of HRT and OC and risk of
clinicopathological and molecular subsets of CRC.* Correspondence: jenny.brandstedt@med.lu.se
1Department of Clinical Sciences, Lund, Oncology and Pathology, Lund
University, Skåne University Hospital, Lund, Sweden
2Department of Surgery, Skåne University Hospital, Malmö, Sweden
Full list of author information is available at the end of the article
© 2014 Brändstedt et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly credited.
Brändstedt et al. BMC Cancer 2014, 14:371 Page 2 of 12
http://www.biomedcentral.com/1471-2407/14/371Background
Colorectal cancer (CRC) is the third most common cancer
in westernized countries with approximately 1.2 million
new cases being diagnosed every year [1]. The incidence is
higher among men than women, and this sex difference is
likely related to hormonal factors. Indeed, observational
and experimental evidence suggests that sex hormones,
particularly oestrogen, play a role in colorectal cancer
pathogenesis [2]. Yet, the effect of oestrogen on the risk of
CRC is not fully understood. CRC comprises a heteroge-
neous group of diseases with different sets of genetic and
epigenetic alterations that develop through different carci-
nogenetic pathways, characterized by distinctive models of
genetic instability, subsequent clinical manifestations, and
pathological characteristics. In order to understand how a
particular exposure influences the carcinogenic process,
it is of great importance that the exposure of interest is
studied in relation to molecular alterations. Molecular
pathologic epidemiology (MPE), first proposed in 2010
[2], is a multidisciplinary field that investigates the rela-
tionship between exposure factors with molecular sig-
natures of the tumours.
In a large meta-analysis conducted in 1999, Grodstein
et al. [3] found that hormone replacement therapy
(HRT) use was associated with a decreased risk of colon
cancer of approximately 35%. This association was fur-
ther confirmed by the Women’s Health Initiative (WHI)
Clinical Trial [4,5], a randomized, double-blind placebo
controlled clinical trial, where intervention with oestrogen
plus progestin yielded a 44% reduction in incident CRC,
while oestrogen alone did not appear to affect CRC risk.
The California Teachers study revealed that the risk for
colon cancer was 36% lower among HRT users compared
with never users, and the results did not differ by formula-
tion [6]. Further, the risk was lower among recent HRT
users with increasing duration between 5 and 15 years of
use, but this risk reduction was was not seen in the longest
duration group (more than 15 years of use) [6]. A meta-
analysis of 18 observational studies showed a 20% reduc-
tion in colon cancer incidence among women having ever
used HRT, and duration of HRT use did not influence risk
estimates [7].
Hence, while epidemiological data support a protective
effect of HRT on CRC, the associations between different
combinations of HRT and CRC risk remain unclear. The
results from the WHI, wherein unopposed estrogen did
not appear to affect CRC risk, imply an important protect-
ive role of progestins, but the biological mechanisms
underlying the effect of progestins in the colorectum are
not well understood.
Colorectal carcinogenesis can be regarded as a com-
plex process involving multiple genetic and epigenetic
alterations [8,9]. Accumulating evidence suggests that
the influence of aetiological factors may differ accordingto the carcinogenetic pathway. As traditional cancer
epidemiology-approaches have not generally taken clini-
copathological and key molecular characteristics, e.g.
expression of beta-catenin, cyclin D1, p53 and mis-
match repair proteins [10-13] into account, the impact
of hormonal factors on CRC risk may be further clari-
fied by doing so [14]. So far, studies on associations of
HRT and molecular subgroups of CRC have been limited
and inconsistent [15-17].
The epidemiological evidence for an association between
oral contraceptives (OC) and CRC risk is also somewhat
inconsistent in that some studies have suggested inverse
associations [18-22], whereas others have found no associ-
ations [23-26]. A recent meta-analysis, summarising the
results from seven cohort- and eleven case–control stud-
ies, reported a statistically significant risk reduction of 19%
among ever users of OC compared with never users, al-
though there was no clear risk reduction with increasing
duration of use [27].
Taken together, the findings from these observational
and experimental studies suggest that exogenous sex hor-
mones may play an important role in colorectal carcino-
genesis. The aim of this study was therefore to investigate
the associations of postmenopausal HRT (combina-
tions with oestrogen and progesterone as well as use of
oestrogen alone) and OC use with CRC risk in the
Malmö Diet and Cancer Study (MDCS), a large prosc-
pective population based cohort study. In particular,
we examined risk of CRC according to tumour site, TNM-
stage, expression of beta-catenin-, p 53 and cyclin D1, and
microsatellite instability (MSI) screening status.
Methods
The malmö diet and cancer study
The Malmö Diet and Cancer Study (MDCS) is a
population-based prospective cohort study of male and
female residents in Malmö, Sweden, enrolled between
1991 and 1996. At the end of baseline examinations the
total female cohort consisted of 17035 women, born
1923– 1950 [28]. A questionnaire assessed education,
reproductive factors, exposure to OC, HRT, alcohol
consumption and smoking habits. Weight and length
was measured by a trained nurse and body mass index
(BMI) was calculated as kg/m2. Information on gynae-
cological surgery was retrieved from hospital records.
Ethical permission for the MDCS (Ref. 51/90), and the
present study (Ref. 530/2008), was obtained from the
Ethics Committee at Lund University. Written informed
consent was obtained from each participant.
Exposure assessement
Use of HRT was assessed in two ways. All participants
were asked to keep a diary of medications. Moreover,
medications were recorded in a questionnaire using an
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coded according to the ATC classification. The present
study has divided use of HRT into oestrogen alone
(ERT), and combined HRT (CHRT), assessed as current
use or not. The use of oral contraceptives was assessed
as ever versus never use.
Study population
In total, 17035 women were included in the female cohort
[28]. A woman was considered postmenopausal if she had
undergone (I) bilateral oophorectomy or (II) hysterectomy,
without bilateral oophorectomy, and if she was 55years
of age or (III) if the above criteria were absent and she
affirmed that her menstruations had ceased at least
during 2years prior to baseline examinations.
A total of 12 583 (73.9%) women classified as peri- or
postmenopausal at baseline made up for the study popu-
lation in all HRT analyses. However, in the analyses related
to OC, both pre-, peri- and postmenopausal women were
included in the analysis, i.e. the entire female cohort.
End-point retrieval
Incident cases of invasive CRC in the MDCS were identi-
fied through the Swedish Cancer Registry and vital status
was determined by record linkage with the Swedish Cause
of Death Registry. End of follow-up was 31 December
2009. Information on vital status and cause of death was
obtained from the Swedish Cause of Death Registry until
31 December 2009. Time on study was defined as time
from baseline to diagnosis, death or end of follow-up 31
December 2009. Median time from baseline until diagno-
sis was 8.6 (SD = 4.3) years and the median follow-up time
in the entire cohort was 13.7 (SD = 3.2) years.
Tumour characteristics
Patient and tumour characteristics in the entire cohort
have been described in detail previously [29-31]. In the
female cohort, a total of 304 incident invasive CRC cases
were identified. Forty-five cases were diagnosed with
CRC before baseline examination, i.e. prevalent colorec-
tal cancers, and therefore excluded from the study. Cases
with other prevalent cancers were not excluded from the
study. Of all incident CRC cases, 180 (59.2%) had tumours
located in the colon and 107 (35.2%) had tumours located
in the rectum. All tumours were histopathologically
re-evaluated by a senior pathologist (KJ).
According to the TNM classification, 33 (10.8%) cases
presented in T-stage 1, 30 (9.8%) in T-stage 2, 159 (52.3%)
in T-stage 3 and 47 (15.4%) in T-stage 4. One hundred
and fifty two (50%) cases presented with lymph node
negative (N0) disease, 73 (24.0%) had N1 (1–3 positive
lymph nodes) and 33 (10.9%) N2 (4 or more positive
lymph nodes) disease. Two hundred and thirty seven(78%) patients did not have distant metastases (M0), and
56 (18.4%) had M1 disease.
Tissue microarray construction and
immunohistochemistry
Tissue microarrays (TMAs) had been constructed as
previously described [29,30]. In brief, two 1.0 mm cores
were taken from each tumour and mounted in a new
recipient block using a semi-automated arraying device
(TMArrayer, Pathology Devices, Westminster, MD, USA).
Among the 304 incident CRC cases in the cohort, a
total number of 280 tumours were suitable for TMA-
construction, and as demonstrated previously, there was
no selection bias regarding the distribution of clinico-
pathological characteristics between the TMA cohort
and the full cohort [29].
For immunohistochemical analysis, 4 μm TMA-sections
were automatically pre-treated using the PT-link system
(DAKO, Glostrup, Denmark) and then stained in an Auto-
stainer Plus (DAKO, Glostrup, Denmark). MSI screening
status was evaluated as previously described [32], whereby
tumour samples lacking nuclear staining of mismatch re-
pair proteins MLH1, PMS2, MSH2 or MSH6 were consid-
ered to have a positive MSI screening status. Hereafter,
tumours with a positive MSI screening status are referred
to as MSI and tumours with negative MSI screening status
are referred to as MSS.
Immunohistochemical staining of beta-catenin was
performed and evaluated as previously described [33],
whereby membranous staining was denoted as 0 (present)
or 1 (absent), cytoplasmic staining intensity as 0–2 and
nuclear staining intensity as 0–2. In this study, the ana-
lyses were limited to nuclear expression of beta-catenin.
Cyclin D1 expression was evaluated as previously de-
scribed [30] and p53 positivity was defined as > =50%
tumour cells with strong nuclear staining intensity in
accordance with previous studies [34].
Statistical methods
A Cox proportional hazards analysis was applied in order
to compare risk of CRC and CRC subgroups between
ERT-, CHRT- and non HRT users, as well as between OC
users and non OC users. For the subtype-specific analyses,
the outcome variable was incident CRC with the molecu-
lar marker of interest; all other incident CRCs (including
those with missing or unknown values for the molecular
marker of interest) were considered censored observations
at the date of diagnosis. This yielded relative risks (HR)
with a 95% confidence interval. Time on study was used
as the underlying time scale, defined as time from baseline
to diagnosis, death or end of follow-up 31 December
2009. The proportional hazards assumption was con-
firmed by a log, − log plot [35]. Chi square test was ap-
plied for assessment of the distribution of investigative
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case analysis examined the heterogeneity between dif-
ferent tumour subgroups regarding their association to
anthropometric factors using an unconditional logistic
regression model.
In the multivariate Cox analysis potential confounders
were included, i.e. age (years), educational level, smoking
habits, alcohol consumption and BMI (Table 1). All statis-
tical analyses were conducted using SPSS version 20 (SPSS
Inc., Chicago, IL, USA). A two-tailed p-value less than
0.05 was regarded as statistically significant.
Results
Baseline characteristics
The distribution of risk factors according to use and non
use of HRT and OC is shown in Table 1. There were sig-
nificant differences in the distribution of age, educational
level, smoking status, alcohol consumption and BMI
among users and non users of HRT and OC. Non HRT
users were more often never smokers (p = <0.001), had a
lower level of education (p = <0.001), consumed less alco-
hol (p = <0.001), had a higher BMI (p = <0.001), and a
higher age (p = <0.001), than HRT users. Additionally,
ever users of OC were younger (p = <0.001), had a
higher level of education (p = <0.001), were more often
smokers (p = <0.001), consumed more alcohol (p = <0.001),Table 1 Distribution of risk factors in relation to HRT, ERT, an
Factor (n of subjects with information) Category
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*All values given in percentages unless otherwise indicated.and had a lower BMI (p = <0.001), compared with never
users.HRT use and risk of colorectal cancer subgroups
There were no statistically significant associations between
HRT use, combined (CHRT) or estrogen only (ERT), and
overall CRC risk (Table 2). We found a significantly re-
duced risk of T stage 1 and 2 tumours among current
users of CHRT (HR: 0.30; 95% CI: 0.09-0.96). (Table 2).
There were no associations between neither CHRT nor
ERT use and risk of other particular subgroups of CRC
(Tables 2 and 3).
When stratifying for cancer site, our results indicated
significant associations of HRT use and an overall reduced
risk of rectal, but not colon, cancer (HR: 0.32; 95% CI:
0.14-0.71). Moreover, HRT use was significantly associated
with T stage 1 and 2 (HR: 0.03; 95%: 0.00-0.36), lymph
node negative (HR: 0.22; 95% CI: 0.06-0.77) and non-
metastatic (HR: 0.42; 95% CI: 0.18-0.98) rectal, but not
colon, cancer (Table 4). We also found significant associa-
tions between HRT and cyclin D1 negative- (HR: 0.07;
95% CI: 0.01-0.88) and p53 negative tumours (HR: 0.19;
95% CI: 0.04-0.96) in the rectum (Table 5). Heterogen-
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Table 2 Risk of colorectal cancer, overall and according to clinicopathological factors, in relation to HRT and ERT use
Tumour subgroups HRT use Number of cases HR crude p HR adjusted p
CRC
No 236 1.00 1.00
ERT 24 0.89(0.59-1.35) 0.583 0.94(0.62-1.44) 0.788
CHRT 41 0.74(0.53-1.03) 0.076 0.94(0.67-1.31) 0.701
T stage 1 & 2
No 54 1.00 1.00
ERT 3 0.53(0.17-1.70) 0.284 0.56(0.17-1.80) 0.560
CHRT 3 0.24(0.09-0.77) 0.016 0.30(0.09-0.96) 0.043
T stage 3 & 4
No 156 1.00 1.00
ERT 17 0.93(0.56-1.52) 0.761 1.01(0.61-1.67) 0.966
CHRT 32 0.87(0.59-1.27) 0.471 1.14(0.77-1.68) 0.511
N0
No 119 1.00 1.00
ERT 14 1.03(0.59-1.79) 0.912 1.15(0.66-2.01) 0.615
CHRT 22 0.79(0.50-1.24) 0.302 1.05(0.66-1.67) 0.838
N1 & N2
No 79 1.00 1.00
ERT 7 0.75(0.35-1.63) 0.471 0.78(0.36-1.68) 0.522
CHRT 15 0.81(0.47-1.40) 0.449 0.95(0.54-1.67) 0.860
M0
No 181 1.00 1.00
ERT 20 0.96(0.61-1.52) 0.863 1.04(0.66-1.66) 0.861
CHRT 34 0.80(0.55-1.15) 0.232 1.03(0.71-1.49) 0.893
M1
No 45 1.00 1.00
ERT 4 0.78(028–2.16) 0.632 0.77(0.28-2.16) 0.625
CHRT 7 0.66(0.30-1.47) 0.311 0.80(0.36-1.80) 0.589
Adjusted for age, bmi, educational level, smoking habits and alcohol consumption.
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subgroups
As demonstrated in Table 6, there was a statistically sig-
nificant inverse association between ever-use of OC and
overall CRC risk (HR: 0.56; 95% CI: 0.44-0.71) in un-
adjusted analysis. However, after adjustment for well-
established risk factors of CRC, i.e. age, BMI, alcohol
consumption, smoking habits and educational level, this
significant association was lost.
Similar statistically significant inverse associations were
seen between OC use and the majority of clinicopathologi-
cal and molecular subgroups, except for lymph node posi-
tive disease, negative nuclear betacatenin expression and
MSS tumours (Table 6). Again, no statistically significant
results were seen after adjustment for established risk
factors.
In the analysis stratified for cancer site, a significantly in-
creased risk was found of lymph node positive (HR: 1.81
95% CI: 1.00-3.28) and non-metastatic disease (HR: 1.55;
95% CI: 1.00-2.40), as well as for cyclin D1 positive tu-
mours (HR: 1.62 95% CI: 1.04-2.51) in the colon (Table 7).
No associations were found between OC use and specific
subgroups of rectal cancer, or overall risk for colon or
rectal cancer. No significant heterogeneity was found
between tumour subgoups.Discussion
In this prospective cohort study, we present data on as-
sociations between use of HRT and OC and overall risk
of CRC, as well as risk of different clinicopathological
and molecular subgroups thereof. It should be pointed
out that, due to the limited number of cases available in
the subgroup analyses, the associations were rather mod-
est. In the present study, we could not demonstrate the
expected risk reduction of HRT use and CRC use, which
is in contrast with findings from several previous studies
[3,36-39], as well as with three large meta-analyses, dem-
onstrating a significantly lower incidence of CRC with use
of combined hormone therapy [7,40,41]. As regards asso-
ciations with TNM stage in the entire cohort, we found a
significantly reduced risk of T-stage 1 and 2 tumours,
but not of any other particular subgroups of CRC.
When stratifying for cancer site, we found a significant
risk reduction for CHRT use and overall risk of rectal,
but not colon, cancer. Significant associations were also
seen between CHRT use and risk of T-stage 1 and 2 tu-
mours, lymph node negativity, non metastatic disease,
cyclin D1 negativity and p53 negativity for tumours
located in the rectum. Again, it must be emphasized
that these results are based on a very limited number of
cases. Previous studies on HRT and risk of colon and
Table 3 Risk of colorectal cancer and molecular subgroups in relation to HRT and ERT use
Tumour subgroups HRT use n HR crude p HR adjusted p
beta-catenin +
No 126 1.00 1.00
ERT 13 0.93(0.52-1.64) 0.790 1.04(0.58-1.84) 0.902
CHRT 19 0.64(0.40-1.04) 0.074 0.87(0.53-1.42) 0.868
beta-catenin −
No 80 1.00 1.00
ERT 7 0.76(0.35-1.65) 0.490 0.77(0.36-1.68) 0.516
CHRT 13 0.69(0.39-1.24) 0.217 0.83(0.46-1.50) 0.533
cyclin D1 +
No 173 1.00 1.00
ERT 16 0.81(0.49-1.35) 0.416 0.87(0.52-145) 0.591
CHRT 29 0.72(0.48-1.06) 0.096 0.93(0.63-1.39) 0.734
cyclin D1 −
No 31 1.00 1.00
ERT 4 1.16(0.41-3.28) 0.782 1.26(0.44-3.59) 0.661
CHRT 5 0.68(0.27-1.75) 0.425 0.84(0.32-2.19) 0.721
p53 +
No 99 1.00 1.00
ERT 11 0.98(0.53-1.83) 0.956 1.07(0.57-1.99) 0.843
CHRT 18 0.78(0.47-1.29) 0.334 1.00(0.59-1.65) 0.970
p53 −
No 107 1.00 1.00
ERT 9 0.74(0.37-1.45) 0.374 0.79(0.40-1.55) 0.488
CHRT 16 0.63(0.38-1.07) 0.089 0.84(0.49-1.42) 0.508
MSI
No 38 1.00 1.00
ERT 1 0.23(0.03-1.63) 0.140 0.24(0.03-1.72) 0.154
CHRT 5 0.56(0.22-1.43) 0.225 0.80(0.31-2.06) 0.649
MSS
No 164 1.00 1.00
ERT 18 0.97(0.60-1.58) 0.903 1.06(0.65-1.72) 0.829
CHRT 28 0.73(0.49-1.09) 0.120 0.92(0.61-1.39) 0.700
Adjusted for age, bmi, educational level, smoking habits and alcohol consumption.
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ging results. Most studies report a similar risk reduction
for both colon- and rectal cancer [40-42], however at
least two studies reported a significantly lower risk of
colon, but not rectal, cancer, with the use of HRT [6,37].
The potential biological mechanisms underlying the dif-
ferences in risk related to location remain unclear.
The most frequently cited study on this subject is the
Women’s Health Initiative Trial [4], that demonstrated a
44% risk reduction with continous combined estrogen
plus progesterin therapy compared to the placebo group,
whereas unopposed estrogen therapy was not associated
with a decreased CRC risk. However, despite the convin-
cing risk reduction of 44%, the WHI clinical trial raises
several questions. Firstly, follow-up time was only 5.2 years
in this trial, and consequently, information on long term
effects is lacking. Secondly, despite the fact that women
taking HRT at the time of diagnosis had a larger extent of
lymph node positive disease and more advanced clinical
stage, mortality from CRC was not decreased in this cat-
egory. Therefore, the clinical relevance of these results
needs to be further discussed.Concerning the effects of combined versus unopposed
estrogen therapy, results are diverging. The WHI pre-
sented no risk reduction of unopposed estrogen, which
is in line with the findings by Newcomb et al. [37], who
reported an inverse association between CRC risk and
current combined HRT in a large case–control study,
but no association with unopposed estrogen therapy. In
contrast to these findings, both the California Teacher
Study and Campbell et al. reported a lower risk of CRC
among ever users of HRT, but no difference in risk by
formulation [20].
Few previous studies have addressed the possible inter-
action between hormone therapy use and CRC risk in re-
lation to clinical disease stage at diagnosis. Grodstein et al.
reported a similar risk reduction with hormone therapy
for higher and lower stages [43]. In the California Teachers
study, the association between HRT and reduced CRC risk
was stronger for more advanced stages [6]. However, in
both the California Teachers Study, and the Womens
Health Trial, the difference in clinical stage at time of diag-
nosis may be due to the high level of screening-detected
cases among these patients, hence being in an earlier stage
Table 4 Risk of CRC and clinicopathological subgrops in relation to HRT and ERT use in colon and rectum
Colon Rectum
Tumour subgroups HRT use n HR crude p HR adjusted p n HR crude p HR adjusted p
CRC
No 150 1.00 1.00 81 1.00 1.00
ERT 15 1.21(0.71-2.06) 0.488 1.17(0.67-2.02) 0.584 8 0.49(0.23-1.03) 0.061 0.38(0.17-0.86) 0.020
CHRT 28 1.04(0.68-1.57) 0.873 1.16(0.74-1.80) 0.521 13 0.44(0.23-0.86) 0.017 0.32(0.14-0.71) 0.005
T stage 1 & 2
No 27 1.00 1.00 24 1.00 1.00
ERT 1 0.52(0.07-3.89) 0.525 0.34(0.04-2.70) 0.308 2 0.32(0.07-1.45) 0.138 0.11(0.02-0.67) 0.017
CHRT 1 0.21(0.03-1.54) 0.125 0.24(0.03-1.90) 0.178 2 0.09(0.01-0.76) 0.026 0.03(0.00-0.36) 0.031
T stage 3 & 4
No 117 1.00 1.00 42 1.00 1.00
ERT 13 1.29(0.73-2.30) 0.381 1.30(0.72-2.35) 0.384 4 0.53(0.19-1.48) 0.223 0.51(0.17-1.55) 0.233
CHRT 24 1.17(0.75-1.83) 0.486 1.27(0.78-2.04) 0.335 8 0.72(0.33-1.58) 0.414 0.74(0.28-1.94) 0.533
N0
No 72 1.00 1.00 45 1.00 1.00
ERT 11 1.72(0.91-3.26) 0.096 1.54(0.79-3.00) 0.203 3 0.36(0.11-1.20) 0.097 0.31(0.08-1.13) 0.076
CHRT 16 1.20(0.70-2.08) 0.508 1.49(0.83-2.67) 0.183 6 0.29(0.10-0.85) 0.024 0.22(0.06-0.77) 0.222
N1 & N2
No 64 1.00 1.00 18 1.00 1.00
ERT 4 0.76(0.28-2.10) 0.596 0.79(0.28-2.23) 0.659 3 1.03(0.30-3.56) 0.959 1.00(0.26-3.92) 1.000
CHRT 10 0.90(0.46-1.77) 0.762 0.79(0.37-1.65) 0.522 5 1.18(0.42-3.34) 0.757 1.00(0.27-3.73) 1.000
M0
No 114 1.00 1.00 64 1.00 1.00
ERT 13 1.38(0.77-2.46) 0.277 1.25(0.69-2.26) 0.471 7 0.54(0.24-1.20) 0.130 0.43(0.18-1.03) 0.057
CHRT 22 1.10(0.69-1.74) 0.695 1.21(0.74-1.97) 0.446 12 0.54(0.29-1.09) 0.084 0.42(0.18-0.98) 0.044
M1
No 32 1.00 1.00 13 1.00 1.00
ERT 3 1.04(0.32-3.40) 0.953 1.24(0.37-4.16) 0.732 1 0.31(0.04-2.48) 0.269 0.32(0.03-3.24) 0.335
CHRT 6 1.06(0.44-2.56) 0.900 1.13(0.42-3.00) 0.809 1 0.14(0.02-1.22) 0.075 0.06(0.00-1.18) 0.064
Adjusted for age, bmi, educational level, smoking habits and alcohol consumption.
Brändstedt et al. BMC Cancer 2014, 14:371 Page 7 of 12
http://www.biomedcentral.com/1471-2407/14/371at diagnosis. In the present study, we found a significantly
reduced risk of T stage 1 and 2 tumours among current
users of CHRT, and for rectal cancers this risk reduction
was also seen for lymph node negative and non-metastatic
disease, i.e. less advanced clinical stages.
The relationship between postmenopausal hormone
therapy and molecular subtypes of CRC has not yet
been thoroughly studied [15,44]. However, a recent
study investigated the relationship between HRT use
and MSI, BRAF and CIMP status of the tumours [15],
whereby HRT (ever vs never use) was inversely associ-
ated with overall CRC risk, lower risk for MSI-L/MSS
tumours and borderline significantly lower risks for
CIMP-negative and BRAF-wildtype tumours, suggest-
ing that HRT may have more pronounced inhibitory
effects on the”traditional” pathway, as compared to the
serrated or alternate pathways, of colorectal carcino-
genesis. Additionally, Lin et al. found no associations
between HRT and CRC risk according to MSI or p 53
status [44]. In this present study, we did not find any
associations between current use of HRT and risk of
CRC according to molecular features of the tumours in
the overall analysis. However, as already mentioned, in
stratified analysis according to tumour location, we founda lower risk of cyclin D1 and p53 negative tumours in
the rectum.
When evaluating the associations between ever use of
OC and CRC risk, we found no significant results in the
analyses adjusted for established risk factors of CRC.
However, in the unadjusted analysis, a significant risk
reduction was seen for OC use and all CRC subgroups,
except lymph-node positive disease, negative nuclear
beta-catenin expression and MSS tumours. The analysis
was repeated including one additional covariate in sep-
arate models. The association between OC and all stud-
ied subgroups remained statistically significant in all
models except the one including age at baseline, and
also after inclusion of menopausal status in the analysis
(data not shown).
For cancers located in the colon, contrasting associa-
tions were found, with an increased risk of lymph node-
positive and non-metastatic tumours, as well as for cyclin
D1 positive tumours.
The epidemiologic evidence for a causal link between
OC and CRC risk has not been consistent [19-22,24-26].
To our knowledge, only two previous studies have
adressed the question whether this potential association
is influenced by molecular features of the tumours.
Table 5 Risk of CRC and molecular subgroups in relation to HRT and ERT use in colon and rectum
Colon Rectum
Tumour subgroups HRT use n HR crude p HR adjusted p n HR crude p HR adjusted p
beta-catenin +
No 68 1.00 1.00 51 1.00 1.00
ERT 9 1.62(0.80-3.26) 0.180 1.52(0.74-3.16) 0.257 4 0.38(0.14-1.09) 0.073 1.00(0.45-2.25) 1.000
CHRT 11 0.88(0.46-1.67) 0.696 0.96(0.48-1.91) 0.910 8 0.44(0.19-1.02) 0.054 1.00(0.44-2.26) 1.000
beta-catenin −
No 64 1.00 1.00 17 1.00 1.00
ERT 4 0.76(0.27-2.09) 0.588 0.71(0.25-1.97) 0.506 3 0.87(0.24-3.12) 0.833 1.00(0.27-3.73) 1.000
CHRT 10 0.91(0.46-1.78) 0.779 0.92(0.45-1.88) 0.808 3 0.41(0.09-1.83) 0.242 1.00(0.25-3.95) 1.000
cyclin D1 +
No 120 1.00 1.00 50 1.00 1.00
ERT 10 1.04(0.54-1.98) 0.917 0.96(0.49-1.86) 0.895 6 0.56(0.23-1.34) 0.189 0.44(0.17-1.14) 0.091
CHRT 18 0.86(0.52-1.42) 0.557 0.95(0.56-1.62) 0.854 11 0.60(0.28-1.28) 0.188 0.51(0.21-1.24) 0.135
cyclin D1 −
No 15 1.00 1.00 16 1.00 1.00
ERT 3 2.05(0.59-7.10) 0.260 2.34(0.65-8.44) 0.196 1 0.37(0.05-2.81) 0.334 0.28(0.03-2.27) 0.232
CHRT 4 1.33(0.44-4.05) 0.615 1.50(0.46-4.94) 0.504 1 0.19(0.02-1.56) 0.124 0.07(0.01-0.88) 0.039
p53 +
No 54 1.00 1.00 40 1.00 1.00
ERT 6 1.38(0.59-3.24) 0.454 1.27(0.53-3.02) 0.588 5 0.54(0.21-1.41) 0.208 1.00(0.43-2.35) 1.000
CHRT 9 0.94(0.46-1.92) 0.869 1.02(0.48-2.20) 0.951 9 0.56(0.25-1.27) 0.168 1.00(0.42-2.40) 1.000
p53 −
No 82 1.00 1.00 26 1.00 1.00
ERT 7 1.02(0.47-2.21) 0.968 0.95(0.43-2.11) 0.903 2 0.47(0.11-2.02) 0.308 0.23(0.05-1.18) 0.078
CHRT 13 0.89(0.49-1.61) 0.703 1.00(0.54-1.86) 0.996 3 0.36(0.09-1.54) 0.170 0.19(0.04-0.96) 0.044
MSI
No 36 1.00 1.00 2 1.00 1.00
ERT 1 0.36(0.05-2.67) 0.320 0.28(0.04-2.08) 0.212 0 - -
CHRT 5 0.84(0.32-2.16) 0.710 0.90(0.34-2.40) 0.832 0 - -
MSS
No 97 1.00 1.00 64 1.00 1.00
ERT 11 1.35(0.72-2.53) 0.349 1.36(0.71-2.60) 0.352 7 0.54(0.24-1.22) 0.138 1.00(0.49-2.03) 1.000
CHRT 17 0.98(0.58-1.65) 0.943 1.08(0.62-1.89) 0.789 11 0.46(0.22-0.97) 0.041 1.00(0.49-2.05) 1.000
Adjusted for age, bmi, educational level, smoking habits and alcohol consumption.
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http://www.biomedcentral.com/1471-2407/14/371Newcomb et al. have previously studied the association
between HRT and MSI status of the tumours and found
no association with MSI high tumours, but a risk re-
duction of 20% for MSI-low/MSS tumours [16,45], and
no difference in risk according to tumour location.
Additionally, Slattery et al. demonstrated a lower risk
of MSI positive tumours among both recent HRT users
and OC users [16].
Based on results from emerging translational research,
several molecular models have been described to account
for the clinicopathological heterogeneity in colorectal car-
cinogenesis [10-12,34,46,47]. The potential mechanisms
by which hormone therapy use reduces risk of CRC devel-
opment remain unclear. Experimental studies on mice
and cell lines have shown that oestrogen- or progesterone-
activated signaling leads to growth inhibiting effects on
colon cancer cells by upregulating several cell cycle regula-
tors such as p 21, p27 and p53 [48,49]. It has also been
proposed that estrogen treatment maintains genomic
stability in colonic epithelial cells through upregulation
of mismatch repair genes [16,50]. Epigenetic events mayalso play an important role, as estrogen may be a key
factor in the pathway leading to the CpG-island hyper-
methylation (CIMP) phenotype [51].
General strengths of our study include the population-
based, prospective design, the ability to control for mul-
tiple potential confounding factors in multivariate risk
models and the molecular pathological epidemiology ap-
proach linking life style exposures to different tumour
markers [14].
Information on HRT use was provided from two dif-
ferent sources, a diary as well as a questionnaire, thus
optimising the opportunity to include all HRT-users and
minimising the number of under-reporters. We consider
our data on HRT to be valid and reliable. This study used
two HRT categories, namely current and non-users, which
is a limitation as the non-user cohort probably included
former users. Such a misclassification is likely to lead to
an attenuation of risks and, if anything, observed risks
may be underestimated. Regarding exposure to OC, the
risk of misclassification is probably lower, since we have
used ever vs never use, and most women are peri- or
Table 6 Risk of colorectal cancer, overall and according to clinicopathological factors, in relation to oral contraceptive
(OC) use
Tumour subgroups OC use n HR crude p HR adjusted p
CRC
No 194 1.00 1.00
OC 107 0.56(0.44-0.71) <0.001 1.05(0.80-1.37) 0.738
T stage 1 & 2
No 45 1.00 1.00
OC 17 0.39(0.22-0.68) 0.001 0.69(0.37-1.28) 0.239
T stage 3 & 4
No 127 1.00 1.00
OC 77 0.62(0.47-0.82) 0.001 1.21(0.87-1.67) 0.254
N0
No 105 1.00 1.00
OC 46 0.45(0.32-0.63) <0.001 0.82(0.56-1.22) 0.328
N1 & N2
No 60 1.00 1.00
OC 45 0.78(0.52-1.13) 0.176 1.36(0.88-2.11) 0.173
M0
No 150 1.00 1.00
OC 85 0.58(0.44-0.75) <0.001 1.05(0.78-1.42) 0.744
M1
No 38 1.00 1.00
OC 17 0.46(0.26-0.81) 0.007 0.90(0.47-1.70) 0.734
beta-catenin+
No 105 1.00 1.00
OC 51 0.50(0.35-0.70) <0.001 0.97(0.66-1.41) 0.853
beta-catenin−
No 61 1.00 1.00
OC 42 0.70(0.47-1.04) 0.076 1.31(0.84-2.05) 0.232
cyclin D1+
No 138 1.00 1.00
OC 75 0.55(0.42-0.74) <0.001 1.16(0.85-1.60) 0.351
cyclin D1−
No 30 1.00 1.00
OC 15 0.51(0.27-0.94) 0.032 0.63(0.32-1.27) 0.199
p53+
No 81 1.00 1.00
OC 46 0.58(0.41-0.83) 0.003 1.06(0.70-1.60) 0.744
p53−
No 88 1.00 1.00
OC 45 0.52(0.36-0.74) <0.001 1.04(0.70-1.56) 0.840
MSI
No 28 1.00 1.00
OC 17 0.62(0.34-1.13) 0.117 1.78(0.92-3.47) 0.088
MSS
No 136 1.00 1.00
OC 74 0.56(0.42-0.74) <0.001 0.98(0.71-1.36) 0.912
Adjusted for age, bmi, educational level, smoking habits and alcohol consumption.
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http://www.biomedcentral.com/1471-2407/14/371postmenopausal at baseline and will most probably not
start treatment with oral contraceptives by that time.
Information on duration of exposure of both HRT and
OC is lacking in this study, which may have provided
deeper knowledge on the associations with CRC risk.
A limitation to the present study is the relatively small
number of cases in some subgroups, particularly in the
analyses stratified for tumour location. This generates
large confidence intervals and, subsequently, low statistical
power and the possibility that some of the non-significant
findings may have been caused by a potential type II error.
Therefore, we regard our study as primarily explorative.
To our best knowledge, no studies have described the
associations of HRT and OC use and risk of CRC definedby the herein investigated biomarkers. Furthermore, we
have no à priori hypothesis on the direction of the possible
associations. Given the discovery-driven nature of this
study, we consider it important not to increase the risk of
a potential type II error by adjusting p-values. Instead, any
identified associations will need confirmation in future
studies.
Although there are several challenges to molecular epi-
demiological pathology studies, for example multiple hy-
pothesis testing, misclassification of tumour endpoints,
and sample size, the discipline also has unique strengths.
MPE can provide insights into mechanisms related to
both CRC initiation and progression, in order to optimize
personalised prevention and therapy strategies [52]. By
Table 7 Risk of colorectal cancer, overall and according to clinicopathological factors, in relation to oral contraceptive
(OC) use in colon and rectum
Colon Rectum
Tumour subgroups OC use n HR crude p HR adjusted p n HR crude p HR adjusted p
CRC
No 116 1.00 1.00 69 1.00 1.00
OC 59 1.00(0.73-1.37) 0.998 1.41(0.96-2.08) 0.080 37 1.02(0.68-1.53) 0.934 0.97(0.59-1.60) 0.900
T stage 1&2
No 22 1.00 1.00 21 1.00 1.00
OC 8 0.72(0.32-1.62) 0.422 1.43(0.56-3.66) 0.462 8 0.76(0.33-1.76) 0.521 0.67(0.23-1.89) 0.445
T stage 3 &4
No 89 1.00 1.00 34 1.00 1.00
OC 49 1.08(0.76-1.54) 0.655 1.43(0.93-2.22) 0.107 24 1.22(0.72-2.07) 0.460 1.27(0.64-2.53) 0.488
N0
No 63 1.00 1.00 37 1.00 1.00
OC 26 0.77(0.49-1.22) 0.271 1.17(0.67-2.03) 0.582 18 0.93(0.52-1.66) 0.811 0.90(0.43-1.88) 0.780
N1 & N2
No 43 1.00 1.00 17 1.00 1.00
OC 30 1.38(0.86-2.20) 0.181 1.81(1.00-3.28) 0.051 12 1.20(0.57-2.52) 0.630 1.00(0.39-2.56) 1.000
M0
No 88 1.00 1.00 57 1.00 1.00
OC 47 1.05(0.73-1.49) 0.804 1.55(1.00-2.40) 0.050 31 1.00(0.64-1.56) 0.999 0.83(0.47-1.45) 0.507
M1
No 26 1.00 1.00 9 1.00 1.00
OC 12 0.90(0.45-1.80) 0.771 0.96(0.41-2.30) 0.955 5 1.09(0.35-3.36) 0.880 1.75(0.44-6.86) 0.425
beta-catenin+
No 56 1.00 1.00 43 1.00 1.00
OC 24 0.84(0.52-1.37) 0.489 1.36(0.75-2.47) 0.308 24 1.02(0.62-1.70) 0.931 1.00(0.53-1.88) 1.000
beta-catenin−
No 45 1.00 1.00 14 1.00 1.00
OC 29 1.27(0.79-2.03) 0.322 1.70(0.97-3.00) 0.065 10 1.41(0.61-3.24) 0.421 1.00(0.35-2.87) 1.000
cyclin D1+
No 88 1.00 1.00 44 1.00 1.00
OC 46 1.04(0.72-1.47) 0.843 1.62(1.04-2.51) 0.032 24 1.06(0.64-1.76) 0.826 1.04(0.56-1.95) 0.893
cyclin D1−
No 15 1.00 1.00 14 1.00 1.00
OC 8 1.00(0.42-2.36) 0.999 0.90(0.31-2.60) 0.844 7 0.82(0.33-2.03) 0.666 0.77(0.24-2.48) 0.660
p53+
No 45 1.00 1.00 32 1.00 1.00
OC 20 0.90(0.52-1.53) 0.685 1.28(0.67-2.45) 0.451 22 1.37(0.78-2.39) 0.274 1.00(0.49-2.02) 1.000
p53−
No 59 1.00 1.00 26 1.00 1.00
OC 34 1.11(0.73-1.70) 0.625 1.54(0.90-2.63) 0.115 9 0.59(0.28-1.27) 0.177 0.52(0.21-1.30) 0.161
MSI
No 25 1.00 1.00 2 1.00 1.00
OC 14 1.08(0.56-2.09) 0.809 1.85(0.82-1.18) 0.139 0 - -
MSS
No 76 1.00 1.00 54 1.00 1.00 1.000
OC 39 1.02(0.69-1.50) 0.938 1.43(0.89-2.32) 0.143 32 1.10(0.70-1.72) 0.678 1.00(0.58-1.74)
Adjusted for age, bmi, educational level, smoking habits and alcohol consumption.
Brändstedt et al. BMC Cancer 2014, 14:371 Page 10 of 12
http://www.biomedcentral.com/1471-2407/14/371interdisciplanary collaboration and education of epidemiol-
ogists in molecular pathology, and pathologists in epidemi-
ology and biostatistics, this interdisciplinary field of MPE
can be further elaborated. Along with the well described
CIN, MSI and DNA methylation pathways of colorectal
carcinogenesis, it has further been proposed that other
systems and pathways are involved in the pathogenesis
of CRC, such as inflammation, and that microRNAs can
actively contribute to the carcinogenic process [53].
Conclusions
In conclusion, our findings provide information on the re-
lationship between use of hormone replacement therapyand oral contraceptives, and risk of colorectal cancer
according to several clinicopathological and molecular
subsets of the disease, also depending on tumour loca-
tion. These findings underline the need for continous
investigation and further translational research address-
ing the effects of hormone therapy on key molecular
events underlying the different pathways of colorectal
carcinogenesis.
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